Home › Companies › Arcutis Biotherapeutics, Inc. › 2024-2025
Compiled from SEC Form N-PX filings and Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 17, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 12, 2025: 5 items on Arcutis Biotherapeutics, Inc.’s Form 8-K, filed June 17, 2025: 5 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Arcutis Biotherapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Arcutis Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bhaskar Chaudhuri, Ph.D. | 69,994,307 | -- | -- | 19,137,532 | 14,767,325 | 79% | Not verified | — |
| Elect Director: Sue-Jean Lin | 75,774,723 | -- | -- | 13,357,116 | 14,767,325 | 85% | Not verified | — |
| Elect Director: Howard G. Welgus, M.D. | 66,289,952 | -- | -- | 22,841,887 | 14,767,325 | 74% | Not verified | — |
| 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 | 103,482,807 | 47,951 | 368,406 | -- | -- | 99.9% | Not verified | — |
| 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers | 74,469,060 | 13,477,586 | 1,185,193 | -- | 14,767,325 | 85% | Not verified | — |
Source: Arcutis Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 17, 2025 — read the filing on EDGAR.
Each item below shows how the 216 asset managers that disclosed a Arcutis Biotherapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Bhaskar Chaudhuri, Ph.D.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Bhaskar Chaudhuri, Ph.D.”): 69,994,307 for, 19,137,532 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 18,555,129 for, 9,168,246 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,679,158 | 0 | 0 | 6,400 | For |
| Prudential/PGIM | 5,192,624 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 2,913,115 | Withhold |
| Fidelity | 2,280,558 | 0 | 0 | 144,841 | Mixed |
| American Century | 0 | 0 | 0 | 1,342,139 | Withhold |
| FRANKLIN STRATEGIC SERIES | 965,545 | 0 | 0 | 0 | For |
| State Street | 877,116 | 0 | 0 | 1,115 | For |
| Charles Schwab | 0 | 0 | 0 | 873,071 | Withhold |
| Invesco | 0 | 0 | 0 | 826,702 | Withhold |
| TIAA | 803,717 | 0 | 0 | 0 | For |
| Federated Hermes | 683,722 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 675,034 | Withhold |
| First Trust | 0 | 0 | 0 | 343,248 | Withhold |
| Royce | 339,399 | 0 | 0 | 0 | For |
| AMG FUNDS | 284,806 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 283,740 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 232,873 | Withhold |
| John Hancock | 182,466 | 0 | 0 | 38,164 | Mixed |
| SEI | 0 | 0 | 0 | 200,058 | Withhold |
| Lincoln Financial | 78,900 | 0 | 0 | 108,569 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 179,695 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 143,879 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 102,700 | Withhold |
| Lazard | 0 | 0 | 0 | 83,302 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 79,198 | Withhold |
Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.
Combines 2 wordings of this item as funds reported it.
74% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Howard G. Welgus, M.D.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Howard G. Welgus, M.D.”): 66,289,952 for, 22,841,887 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 16,849,027 for, 10,874,348 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,679,158 | 0 | 0 | 6,400 | For |
| Prudential/PGIM | 5,192,624 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 2,913,115 | Withhold |
| Fidelity | 2,280,558 | 0 | 0 | 144,841 | Mixed |
| American Century | 0 | 0 | 0 | 1,342,139 | Withhold |
| FRANKLIN STRATEGIC SERIES | 965,545 | 0 | 0 | 0 | For |
| State Street | 2,482 | 0 | 0 | 875,749 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 873,071 | Withhold |
| Invesco | 0 | 0 | 0 | 826,702 | Withhold |
| TIAA | 0 | 0 | 0 | 803,717 | Withhold |
| Federated Hermes | 683,722 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 675,034 | Withhold |
| First Trust | 0 | 0 | 0 | 343,248 | Withhold |
| Royce | 339,399 | 0 | 0 | 0 | For |
| AMG FUNDS | 284,806 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 283,740 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 232,873 | Withhold |
| John Hancock | 182,466 | 0 | 0 | 38,164 | Mixed |
| SEI | 0 | 0 | 0 | 200,058 | Withhold |
| Lincoln Financial | 39,629 | 0 | 0 | 147,840 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 179,695 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 143,879 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 102,700 | Withhold |
| Lazard | 0 | 0 | 0 | 83,302 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 79,198 | Withhold |
Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.
Combines 2 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Sue-Jean Lin
Arcutis Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Sue-Jean Lin”): 75,774,723 for, 13,357,116 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 23,112,216 for, 4,611,159 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,679,158 | 0 | 0 | 6,400 | For |
| Prudential/PGIM | 5,192,624 | 0 | 0 | 0 | For |
| BlackRock | 2,913,115 | 0 | 0 | 0 | For |
| Fidelity | 2,417,199 | 0 | 0 | 8,200 | For |
| American Century | 0 | 0 | 0 | 1,342,139 | Withhold |
| FRANKLIN STRATEGIC SERIES | 965,545 | 0 | 0 | 0 | For |
| State Street | 2,482 | 0 | 0 | 875,749 | Withhold |
| Charles Schwab | 873,071 | 0 | 0 | 0 | For |
| Invesco | 826,702 | 0 | 0 | 0 | For |
| TIAA | 803,717 | 0 | 0 | 0 | For |
| Federated Hermes | 683,722 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 675,034 | Withhold |
| First Trust | 0 | 0 | 0 | 343,248 | Withhold |
| Royce | 339,399 | 0 | 0 | 0 | For |
| AMG FUNDS | 284,806 | 0 | 0 | 0 | For |
| Equitable | 170,380 | 0 | 0 | 113,360 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 232,873 | Withhold |
| John Hancock | 182,466 | 0 | 0 | 38,164 | Mixed |
| SEI | 200,058 | 0 | 0 | 0 | For |
| Lincoln Financial | 39,629 | 0 | 0 | 147,840 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 179,695 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 143,879 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 0 | 0 | 0 | 102,700 | Withhold |
| Lazard | 0 | 0 | 0 | 83,302 | Withhold |
| RBB FUND, INC. | 0 | 0 | 0 | 79,198 | Withhold |
Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.
Combines 8 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers”): 74,469,060 for, 13,477,586 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,679,158 | 6,400 | 0 | 0 | For |
| Prudential/PGIM | 5,192,624 | 0 | 0 | 0 | For |
| BlackRock | 2,913,115 | 0 | 0 | 0 | For |
| Fidelity | 136,641 | 2,288,758 | 0 | 0 | Mixed |
| American Century | 0 | 1,342,139 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 965,545 | 0 | 0 | 0 | For |
| State Street | 877,116 | 1,115 | 0 | 0 | For |
| Charles Schwab | 873,071 | 0 | 0 | 0 | For |
| Invesco | 0 | 826,702 | 0 | 0 | Against |
| TIAA | 803,717 | 0 | 0 | 0 | For |
| Federated Hermes | 683,722 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 675,034 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 657,134 | 0 | 0 | 0 | For |
| First Trust | 0 | 343,248 | 0 | 0 | Against |
| Royce | 0 | 0 | 339,399 | 0 | Abstain |
| AMG FUNDS | 284,806 | 0 | 0 | 0 | For |
| Equitable | 170,380 | 113,360 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 232,873 | 0 | 0 | Against |
| John Hancock | 182,466 | 38,164 | 0 | 0 | Mixed |
| SEI | 200,058 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,529 | 68,940 | 0 | 0 | Mixed |
| DRIEHAUS MUTUAL FUNDS | 0 | 179,695 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 143,879 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 0 | 102,700 | 0 | 0 | Against |
| Lazard | 0 | 83,302 | 0 | 0 | Against |
Fund voting reports, all 61 managers: 21,303,344 for, 6,727,479 against, 345,840 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 10,584,866 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 9,769,511 | 0 | 0 | 0 | For |
| JENNISON ASSOCIATES LLC | 8,744,006 | 0 | 0 | 0 | For |
| Rubric Capital Management LP | 7,272,483 | 0 | 0 | 0 | For |
| State Street | 3,078,248 | 51,121 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 2,651,442 | 68,940 | 0 | 0 | For |
| BlackRock | 2,633,399 | 27,185 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 2,565,962 | 0 | 0 | Against |
| Ensign Peak Advisors, Inc | 2,001,439 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 0 | 1,519,214 | 0 | 0 | Against |
| American Century | 0 | 1,416,587 | 0 | 0 | Against |
| GW&K Investment Management, LLC | 1,190,009 | 0 | 0 | 0 | For |
| J. Goldman & Co LP | 1,055,857 | 0 | 0 | 0 | For |
| Invesco | 0 | 878,505 | 0 | 0 | Against |
| Charles Schwab | 873,385 | 0 | 0 | 0 | For |
| Nuveen | 815,816 | 0 | 0 | 0 | For |
| PFM Health Sciences, LP | 0 | 705,685 | 0 | 0 | Against |
| Federated Hermes | 701,512 | 0 | 0 | 0 | For |
| UniSuper Management Pty Ltd | 700,000 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 675,034 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0 | 667,447 | 0 | 0 | Against |
| Prudential/PGIM | 591,615 | 0 | 0 | 0 | For |
| Northern Trust | 460,534 | 10,235 | 0 | 0 | For |
| Cormorant Asset Management, LP | 440,817 | 0 | 0 | 0 | For |
| Cercano Management LLC | 0 | 426,101 | 0 | 0 | Against |
Institutional-manager reports, all 177 managers: 56,050,342 for, 11,035,805 against, 259 not voted. Showing the 25 largest; see all in the interactive database.
99.9% Majority: yes · of votes cast
Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
Arcutis Biotherapeutics, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 103,482,807 for, 47,951 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 61 asset managers below reported 27,716,934 for, 6,441 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,685,558 | 0 | 0 | 0 | For |
| Prudential/PGIM | 5,192,624 | 0 | 0 | 0 | For |
| BlackRock | 2,913,115 | 0 | 0 | 0 | For |
| Fidelity | 2,425,399 | 0 | 0 | 0 | For |
| American Century | 1,342,139 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 965,545 | 0 | 0 | 0 | For |
| State Street | 878,231 | 0 | 0 | 0 | For |
| Charles Schwab | 873,071 | 0 | 0 | 0 | For |
| Invesco | 826,702 | 0 | 0 | 0 | For |
| TIAA | 803,717 | 0 | 0 | 0 | For |
| Federated Hermes | 683,722 | 0 | 0 | 0 | For |
| Aberdeen | 675,034 | 0 | 0 | 0 | For |
| First Trust | 343,248 | 0 | 0 | 0 | For |
| Royce | 339,399 | 0 | 0 | 0 | For |
| AMG FUNDS | 284,806 | 0 | 0 | 0 | For |
| Equitable | 283,740 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 232,873 | 0 | 0 | 0 | For |
| John Hancock | 220,630 | 0 | 0 | 0 | For |
| SEI | 200,058 | 0 | 0 | 0 | For |
| Lincoln Financial | 187,469 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 179,695 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 143,879 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 102,700 | 0 | 0 | 0 | For |
| Lazard | 83,302 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 79,198 | 0 | 0 | 0 | For |
Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 119,137,785 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.61% |
| 2 | Prudential/PGIM | 4.36% |
| 3 | BlackRock | 2.45% |
| 4 | Fidelity | 2.04% |
| 5 | American Century | 1.13% |
| 6 | FRANKLIN STRATEGIC SERIES | 0.81% |
| 7 | State Street | 0.74% |
| 8 | Charles Schwab | 0.73% |
| 9 | Invesco | 0.69% |
| 10 | TIAA | 0.67% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 8.88% |
| 2 | Frazier Life Sciences Management, L.P. | 8.20% |
| 3 | JENNISON ASSOCIATES LLC | 7.34% |
| 4 | Rubric Capital Management LP | 6.10% |
| 5 | State Street | 2.63% |
| 6 | FRANKLIN ADVISERS INC | 2.28% |
| 7 | BlackRock | 2.23% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.15% |
| 9 | Ensign Peak Advisors, Inc | 1.68% |
| 10 | Paradigm Biocapital Advisors LP | 1.28% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Suvretta Capital Management, LLC | 8.00% | DEF14A |
| BlackRock | 7.46% | 13F |
| Patrick J. Heron | 7.38% | DEF14A |
| Frazier Life Sciences VIII, L.P. | 7.37% | 13D |
| Rubric Capital Management LP | 6.94% | 13G |
| Vanguard Group | 5.72% | 13F |
| Polar Capital Holdings Plc | 5.29% | DEF14A |
| PRUDENTIAL FINANCIAL INC | 4.45% | 13G |
| Jennison Associates LLC | 4.18% | 13G |
| State Street | 3.76% | 13F |
Percentages above are of 119,137,785 shares outstanding, as reported by Arcutis Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcutis Biotherapeutics, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Arcutis Biotherapeutics, Inc.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 216 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,143 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 85% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcutis Biotherapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2025.
Arcutis Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.